Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 33 (2012), Issue 2, Pages 101-112
http://dx.doi.org/10.3233/DMA-2012-0910

Paraoxonase-1 Is Not Associated with Coronary Artery Calcification in Type 2 Diabetes: Results from the PREDICT Study

Bharti Mackness,1 Judit Marsillach,2 Robert S. Elkeles,3 Ian F. Godsland,3 Michael D. Feher,4 Michael B. Rubens,5 Marcus D. Flather,6 Steve E. Humphries,7 Jackie Cooper,7 and Mike Mackness1

1Pontech Art, Calle De L’Argelagar, Tarragona, Spain
2Medicine (Division of Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA, USA
3Endocrinology and Metabolic Medicine, Imperial College London, St Mary’s Hospital, London, UK
4Beta Cell Unit, Chelsea and Westminster Hospital, London, UK
5CT Scanning Unit, Royal Brompton Hospital, London, UK
6Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK
7The Rayne Institute, Royal Free and University College Medical School, London, UK

Received 11 July 2012; Accepted 11 July 2012

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives: To determine any association between serum paraoxonase-1 (PON1) activity, protein and coding region genetic polymorphisms and coronary artery calcification (CACS) and to determine factors which modulate serum PON1 in type 2 diabetes (T2DM).

Methods and results: 589 patients (419 Caucasian, 120 South Asian, 50 other) from the PREDICT Study were investigated. All patients were asymptomatic for coronary disease and had established T2DM. CACS, lipids, lipoproteins, inflammatory markers, insulin resistance and PON1 activity, concentration and Q192R and L55M genotypes were measured. Independent associations were: 1) PON1 activity negatively with insulin resistance, triglycerides and PON1-55 genotype and positively with PON1-192 genotype; 2) PON1 concentration negatively with Caucasian ethnicity, duration of diabetes and statin use and positively with plasma creatinine and PON1-192 genotype. There was no association between CACS and any of the PON1 activity, concentration or genotype and this finding was not different in the various ethnic groups within the PREDICT study.

Conclusion: PON1 is modulated by a number of factors, some of which are reported here for the first time, including ethnicity and insulin resistance in subjects with T2DM. No association between CACS and PON1 was found.